Durvalumab Wins FDA Approval in Limited-Stage SCLC

(MedPage Today) -- The FDA expanded the indications for the immune checkpoint inhibitor durvalumab (Imfinzi) to include limited-stage small cell lung cancer (SCLC).
Approval stipulates use of the PD-L1 inhibitor in limited-stage SCLC that has...